Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lympho-epithelial Kazal-type inhibitor
- Development stage
- Preclinical
- Lead developer
- Pharis Biotec
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Topical
01
Overview
Pharis Biotec is developing a therapeutic version of the Lympho-Epithelial Kazal-Type Inhibitor (LEKTI) for the treatment of atopic dermatitis. LEKTI is a multi-domain serine protease inhibitor naturally found in the stratum granulosum of the epidermis, where it regulates the activity of kallikrein-related peptidases (KLKs) such as KLK5, KLK7, and KLK14. In atopic dermatitis, a relative deficiency or imbalance of LEKTI leads to uncontrolled protease activity, which degrades corneodesmosomes and triggers pro-inflammatory signaling through PAR2. By delivering exogenous LEKTI, Pharis Biotec aims to restore the skin's protease-antiprotease balance, repair the skin barrier, and alleviate inflammatory symptoms. The project is currently in preclinical development.
- Other names
- Pharis Biotec-LEKTI-Dermatitis, AtopicSPINK5 proteinSPINK-5 proteinSPINK 5 proteinLympho-Epithelial Kazal-Type Inhibitor (PHARIS Biotec)
02
Targets
KLK14 (Kallikrein-related peptidase 14)KLK5 (Kallikrein-related peptidase 5)KLK7
Beyond the preview
Go deeper on lympho-epithelial Kazal-type inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lympho-epithelial Kazal-type inhibitor.